Prophylaxis and treatment in liver transplantation. VII Consensus Document of the Spanish Society of Liver Transplantation

• Published in: Gastroenterología y hepatología Vol. 43; no. 3; p. 169
• Main Authors: Fernández, Inmaculada, Pascasio, Juan Manuel, Colmenero, Jordi
• Format: Journal Article
• Language: English
• Published: Spain 01.03.2020
• Subjects: Alanine Transaminase - blood; Antiviral Agents - therapeutic use; Combined Modality Therapy; DNA, Viral - blood; Drug Resistance, Multiple, Viral; Hepatitis B Antibodies - blood; Hepatitis B Antibodies - therapeutic use; Hepatitis B Core Antigens - immunology; Hepatitis B Surface Antigens - blood; Hepatitis B Vaccines - therapeutic use; Hepatitis B virus - drug effects; Hepatitis B virus - isolation & purification; Hepatitis B, Chronic - blood; Hepatitis B, Chronic - prevention & control; Hepatitis B, Chronic - surgery; Humans; Liver Transplantation - methods; Preoperative Care - methods; Recurrence; Risk Factors; Tissue Donors; Vaccination; Viral Load; Viremia - blood; Core positive grafts; Inmunoglobulina específica; Infección adquirida; Vaccination; Vacuna; Análogos nucleósidos; Donante anticore; Immunoglobulin; Nucleotides; Donor-derived infection
• ISSN: 0210-5705
• DOI: 10.1016/j.gastrohep.2019.11.005

Whilst prophylaxis of hepatitis B is universally accepted after liver transplantation (LT), national recommendations for the prophylaxis and treatment of hepatitis B virus (HBV) infection after LT are lacking in Spain. The aim of the VII consensus meeting organised by the Spanish Society of Liver Transplantation (SETH) was to set recommendations on the prophylaxis and treatment of hepatitis B after LT. The scientific evidence and strength of recommendations was evaluated by using the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) system. This document describes the recommendations and their level of evidence for: the definition and risk factors for hepatitis B recurrence after LT, monitoring and prophylaxis of hepatitis B recurrence at different periods after LT, treatment of hepatitis B before and after LT, and the prophylaxis of HBV infection by the recipients of LT with hepatitis B core antigen positive donors.